Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Polarean Imaging Plc LSE:POLX London Ordinary Share GB00BF3DT583 ORD GBP0.00037
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  4.00 5.63% 75.00 74.00 76.00 76.00 73.50 76.00 543,533 08:00:49
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 1.7 -4.6 -4.3 - 121

Polarean Scientific Presentations on Hyperpolarized 129Xenon at Upcoming Medical Meetings

30/07/2020 1:00pm

Business Wire


Polarean Imaging (LSE:POLX)
Historical Stock Chart


From Apr 2020 to Oct 2020

Click Here for more Polarean Imaging Charts.

- Polarean’s investigational drug/device lung diagnostic to be prominently featured

- Multiple hyperpolarized Xenon MRI presentations to be highlighted at two major upcoming scientific conferences

Polarean Imaging plc (AIM: POLX), the medical‑imaging technology company, with a proprietary drug‑device combination diagnostic for the magnetic resonance imaging (MRI) market, announces a number of presentations highlighting the use of hyperpolarized Xenon 129 (“129Xe”) will be made by leading academic researchers at the upcoming American Thoracic Society (“ATS”) virtual conference and the International Society for Magnetic Resonance in Medicine (“ISMRM”) virtual conference. The ATS and ISMRM conferences are taking place between August 5-10, 2020 and August 8-14, 2020, respectively.

Over 40 abstracts related to the use of hyperpolarized 129Xe were accepted for presentation at ATS 2020. The abstracts listed below are among those that will be presented as posters on Wednesday, August 5, 2020:

ATS 2020 Abstract Title and Lead Author

 

Poster Number

 

Session Number

Coleman EM et al. Hyperpolarized 129Xe Identifies Ventilation Responders to Glycopyrrolate/Formoterol Furmarate in Chronic Obstructive Lung Disease

 

523

 

D28

Bier EA et al. Monitoring Response to Inhaled Prostacyclin Therapy with 129Xenon MR Imaging and Spectroscopy in Patients with Pulmonary Hypertension

 

593

 

B56

Neidbalski PJ et al. Hyperpolarized 129Xe MRI of Regional Capillary-Level Cardio-Pulmonary Dynamics Predict Outcomes in IPF Patients

 

622

 

A68

Bier EA et al. Noninvasive Diagnosis of Pulmonary Hypertension with Hyperpolarized 129Xe Magnetic Resonance Imaging and Spectroscopy

 

633

 

B58

Mummy D et al. Hyperpolarized Xe-129 MRI Measures of Gas Exchange in Non-specific Interstitial Pneumonia

 

705

 

D110

Wang Z et al. Spatial Correlation of 129Xenon Gas Exchange MRI with 99mTc Perfusion Scintigraphy

 

706

 

D110

Wang Z et al. Using 129Xenon MR Gas Exchange MRI to Measure the Membrane and Capillary Components of DLCO and KCO

 

707

 

D110

Mummy D et al. Hyperpolarized 129Xe MRI is sensitive to therapy response in idiopathic pulmonary fibrosis

 

713

 

D110

Shim YM et al. Positive Results from Two Randomized Phase III Trials Assessing Hyperpolarized 129Xenon Gas MRI as a Measure of Regional Lung Function as Compared to Imaging with 133Xenon Scintigraphy

 

1027

 

B39

Presentations of the following accepted abstracts will be delivered at ISMRM on the following days:

ISMRM 2020 Abstract Title and Lead Author

 

Program Number

 

Session Name

Date

Bier EA et al. Noninvasive Diagnosis of Pulmonary Hypertension with Hyperpolarized 129Xe Magnetic Resonance Imaging and Spectroscopy

 

2283

 

Hyperpolarized Gas/Lung MRI

August 8-14

Mummy D et al. Hyperpolarized 129Xe MRI Measures of Gas Exchange in Non-specific Interstitial Pneumonia

 

2291

 

Thoracic & Breast MRI

August 8-14

Niedbalski PJ et al. Imaging Regional Capillary Cardio-Pulmonary Blood Flow Dynamics using Hyperpolarized 129Xe MRI and Keyhole Reconstruction

 

0432

 

Thoracic MRI

August 11

Rankine L et al. Quantitative dose-dependent changes in regional lung function after radiation therapy detected using xenon-129 gas exchange MRI

 

0431

 

Thoracic MRI

August 11

Lu J et al. Bias field correction in hyperpolarized 129Xe ventilation imaging

 

0451

 

Pulmonary Power

August 11

Wang Z et al. A model for interpreting hyperpolarized 129Xe exchange MRI

 

0443

 

Pulmonary Power

August 11

Additionally, Talissa Altes, MD, Professor and Chair of Radiology at the University of Missouri will be delivering a presentation on Xenon lung magnetic resonance imaging (MRI) during the Lung/Thoracic MRI Session W-02 during ISMRM. Session W-02 takes place on Tuesday, August 11, 2020 from 1:45 to 2:30 p.m. ET.

Richard Hullihen, Chief Executive Officer of Polarean commented: “We are pleased to see 129Xenon in MRI highlighted at these key scientific meetings. It is a testament to the growing interest in exploring hyperpolarized 129Xenon as a way of advancing the use of MRI in a non-invasive, non-ionizing functional imaging platform to assist with the early diagnosis of respiratory diseases. As well as this, it can be used to monitor progression and therapeutic response in the patient. Many of the projects being presented at these two leading conferences have made use of Polarean’s products to conduct research, highlighting the growing academic acceptance of the Company’s technology. We hope that the inclusion of so many sessions on 129Xenon will continue to showcase Polarean’s important work in the field as we continue to progress discussions with the regulator regarding the clinical use of our drug-device system.”

About Polarean (www.polarean.com)

The Company and its wholly owned subsidiary, Polarean, Inc. (together the "Group") are revenue-generating, medical drug-device combination companies operating in the high-resolution medical imaging market.

The Group develops equipment that enables existing MRI systems to achieve an improved level of pulmonary function imaging and specializes in the use of hyperpolarized Xenon gas (129Xe) as an imaging agent to visualize ventilation.129Xe gas is currently being studied for visualization of gas exchange regionally in the smallest airways of the lungs, the tissue barrier between the lung, and the bloodstream and in the pulmonary vasculature. Xenon gas exhibits solubility and signal properties that enable it to be imaged within other tissues and organs.

The Group also develops high performance MRI radiofrequency (RF) coils which are a required component for imaging 129Xe in the MRI system. The development of these coils by the Group facilitates emerging applications.

Polarean Imaging plc www.polarean.com / www.polarean-ir.com Richard Hullihen, Chief Executive Officer Via Walbrook PR Jonathan Allis, Chairman

Walbrook PR Tel: +44 (0)20 7933 8780 or polarean@walbrookpr.com Paul McManus / Anna Dunphy Mob: +44 (0)7980 541 893 / +44 (0)7876 741 001

1 Year Polarean Imaging Chart

1 Year Polarean Imaging Chart

1 Month Polarean Imaging Chart

1 Month Polarean Imaging Chart
ADVFN Advertorial
Your Recent History
LSE
POLX
Polarean I..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20201030 23:24:03